drugset / Trial / NCT03565887
Study of Safety and Efficacy of RVL-1201 in the Treatment of Blepharoptosis
RandomizedParallel-groupTriple-blindTreatment
Summary
Phase 3 study to evaluate the safety and efficacy of treatment with RVL-1201 compared to placebo for treatment of blepharoptosis. Eligible subjects will be randomized to one of 2 treatment arms.
Timeline
- Start
- 2018-06-28
- Primary completion
- 2019-04-11
- Completion
- 2019-04-22
Outcome
Met primary endpoint
registry analysis (superiority test); RVL-1201 Ophthalmic Solution 0.1% vs Vehicle Ophthalmic Solution; p <0.0001; ANCOVA; NCT03565887 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Oxymetazoline | Other / unclassified | 0.1 % | Other |